A review of phase 2-3 clinical trial designs
From MaRDI portal
Publication:1029784
DOI10.1007/s10985-007-9049-xzbMath1169.62392OpenAlexW2105329903WikidataQ36925837 ScholiaQ36925837MaRDI QIDQ1029784
Publication date: 13 July 2009
Published in: Lifetime Data Analysis (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s10985-007-9049-x
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Related Items
Methodology and application of adaptive and sequential approaches in contemporary clinical trials, Group-sequential response-adaptive designs for multi-armed trials, A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity, Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials, Discussion on “A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials” by Elena M. Buzaianu and Pinyuen Chen
Cites Work
- Unnamed Item
- Unnamed Item
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Seamlessly Expanding a Randomized Phase II Trial to Phase III
- A Two-Stage Design for Choosing among Several Experimental Treatments and a Control in Clinical Trials
- Designs for Group Sequential Phase II Clinical Trials
- Optimal Designs for a Grouped Sequential Binomial Trial
- Two-stage selection and testing designs for comparative clinical trials
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
- Optimal Dynamic Treatment Regimes
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Phase 2 and 3 Combination Designs to Accelerate Drug Development
